POWERED BY BIOHM
LIVE

Serial Number

97008640

Owner

BIOHM HEALTH INC.

Attorney

Lisa C. Pavento

First Use Date

Dec 31, 2021

Filing Date

Sep 2, 2021

Add to watchlist:

No watchlists yet
View on USPTO

POWERED BY BIOHM Trademark

Serial Number: 97008640 • Registration: 8061014

POWERED BY BIOHM is a trademark filed by BIOHM HEALTH INC. on September 2, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

BIOHM HEALTH INC. (51 trademarks)

425 LITERARY ROAD
CLEVELAND, OH 44113

Entity Type: 99

BIOHM HEALTH LLC (23 trademarks)

CLEVELAND, OH 44113

Entity Type: 16

Trademark Details

Filing Date

September 2, 2021

Registration Date

December 9, 2025

First Use Anywhere

December 31, 2021

First Use in Commerce

December 31, 2021

Published for Opposition

August 16, 2022

Goods & Services

Probiotic supplements; vitamin and mineral supplements; vitamin supplements; whey protein supplements; dietary supplement drink mixes; dietary supplement for eliminating toxins from the intestinal tract; enzyme food supplements; herbal supplements; mineral supplements; multi-vitamin preparations; natural herbal supplements; nutraceuticals for use as a dietary supplement; nutritional supplement for eliminating toxins from the intestinal tract; nutritional supplement shakes; nutritional supplements, namely, probiotic compositions; nutritional supplements, namely, carbohydrates in powdered form; powdered nutritional supplement concentrate; vitamin and mineral supplements in powder, tablet, liquid, capsule or spray form; mineral supplements in powder, tablet, liquid, capsule or spray form; dietary supplements in powder, tablet, liquid, capsule or spray form; food supplements providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; nutritional supplements for human consumption providing a source of vitamins and minerals and essential fatty acids and probiotic cultures in powder, tablet, liquid, capsule or spray form; herbal supplements for general health and well-being, namely, in powder, tablet, liquid, capsule or spray form; nutritional supplements, namely, probiotic compositions in the nature of a vaginal probiotic for the treatment and prevention of bacterial and fungal vaginal infection; nutraceuticals for the treatment and prevention of bacterial vaginosis, vaginal discharge and odors, for preventing the growth of undesirable micro-organisms that can cause vaginal discharge and odor, killing bacteria that cause bacterial vaginosis, and for maintaining a desirable microflora in the vaginal cavity; micro-organisms culture for medical use, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon; pharmaceutical products, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibres in the human organism for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements containing microorganisms and cultures of microorganisms, namely, probiotic lactic acid bacteria, probiotic bifidobacteria which are able to ferment and use the fibers in the human organism; pharmaceutical products for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans for the treatment of diseases, namely, intestinal disorders, diarrhea and to re-equilibrate the intestinal bacterial flora, for the treatment of intestinal inflammations, inflammatory bowel diseases and inflammations of the lower gastrointestinal tract, for the treatment of ulcerative colitis and Crohn's Disease in which inflammation is present both in the small intestine and in the colon, and dietary and nutritional supplements for oral consumption, namely, capsules, tablets, solutions, suspensions, granules, and pellets in dried form, containing micro-organisms cultures, namely, lactic acid bacteria and bifidobacteria having probiotic activity on humans; microbial and biological preparations for medical use, namely, probiotics, for improving the physical well-being of humans, namely, reducing inflammation and pain; dietary supplements for medical use and baby food containing microorganisms, namely, metabolites obtained from the processing of probiotic bacterial cultures; probiotic and nutritional and dietary supplements; antifungal preparations; antifungal creams for medical use; vaginal antifungal preparations; fungal extracts sold as a component ingredient of nutritional supplments and vitamins and bacterial probiotic supplements, and nutritional supplement for digestive health; nutritional supplement for combating digestive disorders such as Crohn's Disease, ulcerative colitis and irritable bowel syndrome; beverages containing probiotic compositions for use as a nutritional supplement; food supplements containing probiotic compositions; human food supplements containing probiotic compositions; animal food products containing probiotic compositions, namely, probiotic animal feed; dietary supplement drink mixes, namely, probiotic compositions in the form of mixes to added to beverages; dietary supplements in the nature of probiotic compositions for mixing with cereal; medical specimens collection kits for the collection of body fluids comprised of swabs for medical purposes, a sealable collection container and sample bag; medical specimens collection kits for the collection of body fluids comprised of swabs for medical purposes, a sealable collection container, sample bag, mailer envelope, ID sticker, and swab applicator; diagnostic biological testing kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic genetic testing kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; diagnostic microbiota testing kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; medical specimen collection kits for the collection of body fluids comprised of medical specimen bags and cups

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 9, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 9, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Nov 17, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Nov 17, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Nov 17, 2025 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 17, 2025 AITU
ASSIGNED TO EXAMINER
Oct 23, 2025 DOCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 21, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 21, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 21, 2025 REAP
USE AMENDMENT FILED
Apr 11, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
Apr 11, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 24, 2024 EXRA
SOU EXTENSION 4 GRANTED
Oct 24, 2024 EX4G
SOU EXTENSION RECEIVED WITH TEAS PETITION
Oct 14, 2024 TPEX
NOTICE OF REVIVAL - E-MAILED
Oct 14, 2024 NREV
PETITION TO REVIVE-GRANTED
Oct 14, 2024 PETG
TEAS PETITION TO REVIVE RECEIVED
Oct 14, 2024 PROA
SOU EXTENSION 4 FILED
Oct 11, 2024 EXT4
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 10, 2024 EXRA
SOU EXTENSION 3 GRANTED
Apr 9, 2024 EX3G
SOU EXTENSION 3 FILED
Apr 9, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Apr 9, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 13, 2023 EXRA
SOU EXTENSION 2 GRANTED
Oct 11, 2023 EX2G
SOU EXTENSION 2 FILED
Oct 11, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Oct 11, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 21, 2023 EXRA
SOU EXTENSION 1 GRANTED
Apr 20, 2023 EX1G
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 19, 2023 ASGN
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 14, 2023 AITU
SOU EXTENSION 1 FILED
Apr 7, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 7, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 11, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 16, 2022 NPUB
PUBLISHED FOR OPPOSITION
Aug 16, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 27, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 14, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 13, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 12, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 12, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 12, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jan 12, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jan 12, 2022 CNRT
ASSIGNED TO EXAMINER
Jan 10, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 15, 2021 NWOS